CorMedix Inc. Gets Preliminary Approval for Derivative Settlement

What Happened
CorMedix Inc. (CRMD) filed an 8-K on August 7, 2026 reporting that on July 24, 2026 the U.S. District Court for the District of New Jersey granted preliminary approval of a proposed settlement resolving consolidated shareholder derivative litigation. The actions include In re CorMedix Inc. Derivative Litigation (Case No. 2:21-cv-18493-JXN-LDW) and a related New Jersey state action, Raval v. Baluch. A final settlement hearing is scheduled for September 23, 2026 before the District Court.

Key Details

• Court: U.S. District Court for the District of New Jersey granted preliminary approval on July 24, 2026.
• Cases: Consolidated federal case In re CorMedix Inc. Derivative Litigation (2:21-cv-18493-JXN-LDW) and related Raval v. Baluch (N.J. Super. Ct. Law Div.).
• Next step: Final settlement hearing set for September 23, 2026.
• Filings: The Notice of Pendency and Proposed Settlement and the Stipulation and Agreement of Settlement were attached as Exhibit 99.1 and Exhibit 99.2 to the 8-K; the 8-K does not disclose a settlement monetary amount.

Why It Matters
Preliminary court approval advances resolution of the company’s shareholder derivative suits, which reduces legal uncertainty while the matter proceeds to a final hearing. Investors should note the settlement is not final until the September 23, 2026 hearing and should review the attached settlement documents for specifics (e.g., any corporate governance changes or remedies) since the 8-K does not state a settlement payment amount.